Free tool
FAERS Monitor: Vpriv
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 022575 or its brand name (Vpriv, Velaglucerase Alfa). Reports on generic versions are filed under their own applications.
Reports
2,052
Serious
1,718
84% of reports
Hospitalization
880
Death reported
280
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- inappropriate schedule of product administration212
- product dose omission issue198
- covid-19167
- fatigue154
- death127
- pyrexia114
- fall112
- malaise111
- weight increased106
- headache105
- infusion related reaction102
- nausea98
- arthralgia95
- abdominal pain93
- weight decreased91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 21 |
| 2012 | 43 |
| 2013 | 74 |
| 2014 | 114 |
| 2015 | 101 |
| 2016 | 97 |
| 2017 | 84 |
| 2018 | 141 |
| 2019 | 158 |
| 2020 | 160 |
| 2021 | 313 |
| 2022 | 224 |
| 2023 | 154 |
| 2024 | 173 |
| 2025 | 112 |
| 2026 | 71 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 102 | 15.8 | 13.1 | 1,401 |
| inappropriate schedule of product administrationSignal | 212 | 12.1 | 10.6 | 2,157 |
| covid-19Signal | 167 | 9.8 | 8.4 | 1,315 |
| product dose omission issueSignal | 198 | 6.9 | 6.0 | 1,007 |
| weight increasedSignal | 106 | 4.9 | 4.0 | 324 |
| abdominal painSignal | 93 | 4.1 | 3.4 | 217 |
| fallSignal | 112 | 3.5 | 2.9 | 195 |
| pyrexiaSignal | 114 | 3.4 | 2.8 | 192 |
| weight decreasedSignal | 91 | 3.3 | 2.7 | 149 |
| malaiseSignal | 111 | 2.6 | 2.2 | 109 |
| arthralgiaSignal | 95 | 2.3 | 1.9 | 73 |
| fatigueSignal | 154 | 2.0 | 1.7 | 82 |
| headache | 105 | 1.7 | 1.4 | 32 |
| death | 127 | 1.5 | 1.3 | 22 |
| nausea | 98 | 1.3 | 1.0 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.